Dogs started on pimobendan typically live months to years longer than they would without it, but the exact timeline depends heavily on when the medication is started and what type of heart disease your dog has. A dog that begins pimobendan in the early, pre-clinical stage of heart disease can gain over a year of additional time before heart failure even develops. A dog already in congestive heart failure has a shorter but still meaningful window, with median survival around 9 months on treatment.
Survival With Early Treatment
The most encouraging data comes from dogs that start pimobendan before they develop symptoms. In a landmark clinical trial known as the EPIC study, dogs with enlarged hearts from mitral valve disease (the most common form of heart disease in dogs) were given either pimobendan or a placebo. The dogs on pimobendan went a median of 1,228 days, roughly 3.3 years, before progressing to heart failure, compared to 766 days (about 2 years) for dogs on placebo. That’s approximately 15 extra months before your dog reaches the point of labored breathing, fluid buildup, and the other hallmarks of congestive heart failure.
This doesn’t mean your dog will live exactly 1,228 days on the medication. Some dogs in that study did far better, others worse. But the takeaway is clear: starting pimobendan when your vet first detects heart enlargement on X-rays or echocardiography, before any symptoms appear, buys significant time.
Survival Once Heart Failure Begins
The picture changes once a dog is already in congestive heart failure. In the QUEST study, which compared pimobendan to an older heart medication in dogs with heart failure from mitral valve disease, dogs on pimobendan survived a median of 267 days (about 9 months) from the start of treatment. Dogs on the older drug survived a median of only 140 days. So pimobendan nearly doubled the survival time in that group, but the overall window is shorter because the disease is more advanced.
Many dogs do live well beyond that 9-month median. The number represents the midpoint, meaning half the dogs lived longer. Some dogs with well-managed heart failure on pimobendan live 18 months or more, particularly smaller breeds with slower disease progression. Others, especially large breeds or dogs with rapid onset, may have less time.
Survival With Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a different type of heart disease that primarily affects large and giant breeds, with Doberman Pinschers being especially prone. In a study focused specifically on Dobermans with preclinical DCM, dogs on pimobendan reached the point of heart failure or sudden death at a median of 718 days (nearly 2 years), compared to 441 days (about 14.5 months) for untreated dogs. That’s roughly 9 additional months.
DCM is generally a more aggressive disease than mitral valve disease, and sudden death is a real risk regardless of medication. Pimobendan helps, but the overall prognosis for DCM tends to be shorter than for valve disease.
How Pimobendan Works
Pimobendan does two things that benefit a failing heart. First, it makes the heart muscle contract more efficiently by helping it use calcium better, so each heartbeat pumps more blood without the heart working harder or demanding more oxygen. Second, it relaxes blood vessels, which lowers the resistance the heart has to pump against. Together, these effects reduce the workload on a struggling heart while improving blood flow throughout the body.
This combination is why pimobendan outperforms older heart medications. It addresses both the weakness of the heart muscle and the strain placed on it by narrowed blood vessels.
What Daily Treatment Looks Like
Pimobendan is given orally twice a day, roughly 12 hours apart, at a total daily dose of 0.5 mg per kilogram of body weight. Most vets recommend giving it on an empty stomach, about an hour before meals, because food can reduce how well the drug is absorbed. The tablets are chewable, which makes dosing easier than with many medications.
Most dogs tolerate pimobendan well. The most commonly reported side effects are decreased appetite, diarrhea, and occasional lethargy. These tend to be mild when they occur. Your vet will likely schedule periodic check-ups with chest X-rays or echocardiograms to monitor how the heart is responding and adjust the overall treatment plan, which often includes a diuretic and other medications once heart failure develops.
When Pimobendan Should Not Be Used
Pimobendan is not appropriate for every type of heart disease. It’s specifically contraindicated in dogs with hypertrophic cardiomyopathy (where the heart muscle is abnormally thick) and aortic stenosis (a narrowing of the main outflow valve). In these conditions, making the heart pump harder can actually be dangerous. This is one reason a proper cardiac workup with imaging is important before starting the medication. Your vet needs to confirm which type of heart disease is present to ensure pimobendan is the right choice.
Factors That Affect Your Dog’s Timeline
No single number can predict how long your individual dog will live on pimobendan. Several factors shift the timeline in meaningful ways:
- Stage at diagnosis: Dogs started on pimobendan in the preclinical stage (heart enlargement but no symptoms) consistently live longer than those who begin after heart failure develops.
- Type of heart disease: Mitral valve disease, which is more common in small breeds, generally has a slower progression than dilated cardiomyopathy in large breeds.
- Breed and size: Small-breed dogs with valve disease often have years ahead of them. Large-breed dogs with DCM face a more compressed timeline.
- Response to combination therapy: Pimobendan is rarely used alone once heart failure starts. How well your dog responds to diuretics and other supportive medications plays a major role.
- Overall health: Kidney function, age, and other concurrent conditions all influence how well a dog tolerates long-term cardiac treatment.
The consistent finding across multiple large clinical trials is that pimobendan extends both survival time and quality of life compared to older treatments or no treatment. For many dogs, it transforms a heart disease diagnosis from an immediate crisis into a manageable chronic condition that allows months or years of comfortable living.